Ratings for DexCom (NASDAQ:DXCM) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ...

Type 2 diabetes patients who take a GLP-1 such as Ozempic or Wegovy are associated with higher usage of continuous glucose monitors, Dexcom said Sept. 5, according to an Investor’s Business Daily ...

Dexcom has rebounded since my last update, but I maintain a 'Hold' rating due to continued overvaluation and limited upside potential. Growth remains solid, especially in sensors and U.S. expansion, ...